when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

onclive·May 6·1 min read

FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC

May 6, 2026·read at onclive ↗

An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC

source

Reporting by onclive.

read at onclive ↗

sharex / twitter linkedin

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

companies & drugs in this story

topics

related stories

May 6Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinomaonclive
May 6Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Canceronclive
May 6Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLConclive
May 6Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myelomaonclive
May 6Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive